Lipids and lipid nanoparticle formulations for delivery of nucleic acids
Inventors
Ansell, Steven M. • Du, Xinyao
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Core Innovation
The invention relates to a compound having a structure of Formula I, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, where L1 and L2 are each independently —O(C5O)— or —(C5O)O—. In Formula I, R1a and R1b are each independently H or C1–C12 alkyl, with additional rules allowing R1b groups to be taken together with adjacent R1b groups to form a carbon–carbon double bond, and analogous selection and double-bond-forming rules apply to R4a and R4b. R2a/R2b and R3a/R3b are each H.
The structure further defines R5 and R6 as each independently methyl or cycloalkyl, and R7 as independently H or C1–C12 alkyl, while R8 and R9 are each independently unsubstituted C1–C12 alkyl or can together form a 5, 6 or 7-membered heterocyclic ring comprising one nitrogen atom. Integer parameters a and d independently range from 0 to 24, b and c independently range from 4 to 12, and e is 1 or 2, with an additional proviso that R1a and R1b are not isopropyl when a is 6 or n-butyl when a is 8. The described compounds are linked to nucleic-acid delivery using lipid-nucleic-acid nanoparticle formulations.
The invention also includes a pegylated lipid structure (II) having alkyl chains R10 and R11 and a PEG parameter z, with stated mean and average molecular weight ranges. The described compositions combine Formula (I) compounds with cationic lipid/cationic components, neutral lipids including DSPC, DPPC, DOPE, or SM, cholesterol, and pegylated lipids including PEG-DMG, with stated molar ratios between components.
Claims Coverage
The consolidated claim coverage identifies 5 inventive feature groups. The first is the Formula I compound scaffold with defined linkages, substituent classes, carbon–carbon double bond-forming options, and parameter constraints. The second is the defined terminal substituent options with cycloalkyl and heterocyclic ring formation. The third is the constrained integer parameters and excluded substituent combinations. The fourth is the pegylated lipid structure (II) and related PEG parameter. The fifth is the composition with nucleic acids and lipid excipients.
Formula I compound scaffold with defined linkage and substituent constraints
A compound having a structure of Formula I (or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof) in which L1 and L2 are each independently —O(C5O)— or —(C5O)O—; R1a and R1b are selected among H or C1–C12 alkyl with an option where R1b together with the carbon atom to which it is bound forms a carbon–carbon double bond with an adjacent R1b; R2a and R2b are each H; and R3a and R3b are each H; R4a and R4b follow the same independent selection logic as R1a/R1b including an option for carbon–carbon double bond formation involving adjacent R4b.
Defined terminal substituent options with cycloalkyl and heterocyclic ring formation
R5 and R6 are each independently methyl or cycloalkyl; R7 is at each occurrence independently H or C1–C12 alkyl; and R8 and R9 are each independently unsubstituted C1–C12 alkyl, or alternatively R8 and R9 together with the nitrogen atom form a 5, 6 or 7-membered heterocyclic ring comprising one nitrogen atom.
Constrained integer parameters and excluded substituent combinations
The compound satisfies integer parameter constraints where a and d are each independently an integer from 0 to 24, b and c are each independently an integer from 4 to 12, and e is 1 or 2, with a proviso that R1a and R1b are not isopropyl when a is 6 or n-butyl when a is 8.
Pegylated lipid structure (II) with defined PEG parameter
A pegylated lipid characterized by structure (II), including alkyl chains R10 and R11 and a PEG parameter z, with stated mean range and average molecular weight ranges in the claim context provided.
Composition with nucleic acids and lipid excipients
A composition that combines the Formula (I) compound with cationic lipid/cationic components, neutral lipids including DSPC, DPPC, DOPE, or SM, cholesterol, and pegylated lipids including PEG-DMG, with stated molar ratios of the compound to neutral lipid, compound to cholesterol, and compound to pegylated lipid.
Overall claim coverage centers on a Formula I compound scaffold with defined L1/L2 linkages, H or C1–C12 alkyl substitution at R1a/R1b and R4a/R4b including possible carbon–carbon double bond formation between adjacent substituents, fixed H at R2a/R2b and R3a/R3b, and numeric parameter bounds with a specific substitution exclusion. Additional coverage extends to pegylated lipid structure (II) and compositions with nucleic acids and lipid components.
Stated Advantages
Nanoparticles shield nucleic acids from serum degradation.
Nanoparticles improve intracellular delivery.
Nanoparticles improve tolerability.
Nanoparticles improve therapeutic index.
Documented Applications
Delivery of nucleic acids, including mRNA, antisense oligonucleotides, miRNA/miRNA inhibitors, siRNA/RNA interference, and plasmid DNA, using lipid-nucleic-acid nanoparticle formulations to treat or prevent diseases.
Interested in licensing this patent?